S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit
The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generat...
Saved in:
| Published in | mBio Vol. 11; no. 5 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
25.09.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2161-2129 2150-7511 2150-7511 |
| DOI | 10.1128/mBio.01991-20 |
Cover
| Abstract | The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation.
The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and peripheral blood mononuclear cells (PBMCs) from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBC levels. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG, and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 were higher in convalescent subjects than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane.
IMPORTANCE
The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation. |
|---|---|
| AbstractList | The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and peripheral blood mononuclear cells (PBMCs) from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBC levels. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG, and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 were higher in convalescent subjects than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane.IMPORTANCE The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation.The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and peripheral blood mononuclear cells (PBMCs) from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBC levels. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG, and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 were higher in convalescent subjects than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane.IMPORTANCE The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation. The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation. The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and peripheral blood mononuclear cells (PBMCs) from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBC levels. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG, and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 were higher in convalescent subjects than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane. IMPORTANCE The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation. The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation. The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and peripheral blood mononuclear cells (PBMCs) from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBC levels. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG, and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 were higher in convalescent subjects than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane. The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and peripheral blood mononuclear cells (PBMCs) from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBC levels. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG, and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 were higher in convalescent subjects than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane. The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation. ABSTRACT The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of the virus and limited preexisting B cell immunity. IgG against the SARS-CoV-2 spike (S) protein, which carries the novel receptor binding domain (RBD), is absent or at low levels in unexposed individuals. To better understand the B cell response to SARS-CoV-2 infection, we asked whether virus-reactive memory B cells (MBCs) were present in unexposed subjects and whether MBC generation accompanied virus-specific IgG production in infected subjects. We analyzed sera and peripheral blood mononuclear cells (PBMCs) from non-SARS-CoV-2-exposed healthy donors and COVID-19 convalescent subjects. Serum IgG levels specific for SARS-CoV-2 proteins (S, including the RBD and S2 subunit, and nucleocapsid [N]) and non-SARS-CoV-2 proteins were related to measurements of circulating IgG MBC levels. Anti-RBD IgG was absent in unexposed subjects. Most unexposed subjects had anti-S2 IgG, and a minority had anti-N IgG, but IgG MBCs with these specificities were not detected, perhaps reflecting low frequencies. Convalescent subjects had high levels of IgG against the RBD, S2, and N, together with large populations of RBD- and S2-reactive IgG MBCs. Notably, IgG titers against the S protein of the human coronavirus OC43 were higher in convalescent subjects than in unexposed subjects and correlated strongly with anti-S2 titers. Our findings indicate cross-reactive B cell responses against the S2 subunit that might enhance broad coronavirus protection. Importantly, our demonstration of MBC induction by SARS-CoV-2 infection suggests that a durable form of B cell immunity is maintained even if circulating antibody levels wane. IMPORTANCE The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key issues are whether humans have preexisting immune memory that provides some protection against SARS-CoV-2 and whether SARS-CoV-2 infection generates lasting immune protection against reinfection. Our analysis focused on pre- and postinfection IgG and IgG memory B cells (MBCs) reactive to SARS-CoV-2 proteins. Most importantly, we demonstrate that infection generates both IgG and IgG MBCs against the novel receptor binding domain and the conserved S2 subunit of the SARS-CoV-2 spike protein. Thus, even if antibody levels wane, long-lived MBCs remain to mediate rapid antibody production. Our study results also suggest that SARS-CoV-2 infection strengthens preexisting broad coronavirus protection through S2-reactive antibody and MBC formation. |
| Author | Embong, A. Karim Sangster, Mark Y. Chaves, Francisco A. Yang, Hongmei Kanagaiah, Preshetha Nguyen-Contant, Phuong Branche, Angela R. Topham, David J. |
| Author_xml | – sequence: 1 givenname: Phuong surname: Nguyen-Contant fullname: Nguyen-Contant, Phuong organization: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 2 givenname: A. Karim surname: Embong fullname: Embong, A. Karim organization: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 3 givenname: Preshetha surname: Kanagaiah fullname: Kanagaiah, Preshetha organization: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 4 givenname: Francisco A. surname: Chaves fullname: Chaves, Francisco A. organization: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 5 givenname: Hongmei surname: Yang fullname: Yang, Hongmei organization: Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 6 givenname: Angela R. surname: Branche fullname: Branche, Angela R. organization: Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA – sequence: 7 givenname: David J. orcidid: 0000-0002-9435-8673 surname: Topham fullname: Topham, David J. organization: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA – sequence: 8 givenname: Mark Y. orcidid: 0000-0002-1599-5894 surname: Sangster fullname: Sangster, Mark Y. organization: David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32978311$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkc9v0zAUxyM0xMbYkSvykUuKfyWOL0hrNbZKQ6AVuFqO_dx5SuzhOEO98aeTrmVQ8MWW_Xmf56fvy-IoxABF8ZrgGSG0edfPfZxhIiUpKX5WnFBS4VJUhBxtz_V0S6g8Ls6G4Q5PizHSMPyiOGZUioYRclL8XKHPKWbwobwBbbJ_ALRcXyIdLPoIfUwbNEcL6LotZscJiAFplyGhq7HXAa3Ob1blIn4rKVoGBztgGUw3WhjQPEVt0d7s8wbliPItoBVFq7Edg8-viudOdwOc7ffT4uuHiy-Lq_L60-VycX5dGl6xXDJu24ZSYxymNVTY1q7hGjfgHNGsFhJ4RSkTxDrTtkQ60gonWrCNrThhmp0Wy53XRn2n7pPvddqoqL16vIhprXTK3nSgsJQSjOCi5Y7rhmjsrHFtW0tRcyzryTXbucZwrzc_dNc9CQlW22RU3_qoHpNRFE8F73cF92PbgzUQctLdwS8OX4K_Vev4oERFcSXlJHi7F6T4fYQhq94PZopFB4jjoCjndS0oacSEvvm711OT35lPANsBJsVhSOCU8Vlvc5ta--7PCPPDEcp_qv4b-YD_Bb17z9I |
| CitedBy_id | crossref_primary_10_1371_journal_ppat_1009352 crossref_primary_10_3390_ijerph182413173 crossref_primary_10_1186_s12884_022_04500_w crossref_primary_10_1016_j_ebiom_2022_103888 crossref_primary_10_1093_cid_ciac057 crossref_primary_10_1126_sciadv_adg0330 crossref_primary_10_17352_jvi_000060 crossref_primary_10_3389_fimmu_2021_696370 crossref_primary_10_1016_j_antiviral_2023_105759 crossref_primary_10_1016_j_biopha_2025_117936 crossref_primary_10_1002_eji_202149655 crossref_primary_10_3389_fimmu_2022_988536 crossref_primary_10_3390_covid1010006 crossref_primary_10_1002_jmv_28584 crossref_primary_10_1016_j_isci_2022_103951 crossref_primary_10_1016_j_jiph_2025_102744 crossref_primary_10_3389_fimmu_2021_614676 crossref_primary_10_1007_s15010_021_01664_z crossref_primary_10_1038_s41467_021_23977_1 crossref_primary_10_3389_fimmu_2024_1396603 crossref_primary_10_17650_1726_9784_2021_20_4_10_17 crossref_primary_10_1016_j_jim_2023_113457 crossref_primary_10_1093_immadv_ltab027 crossref_primary_10_1126_science_abe1107 crossref_primary_10_1016_j_medj_2021_08_001 crossref_primary_10_1016_j_vaccine_2024_04_034 crossref_primary_10_1002_JLB_4COVCRA0721_356RRR crossref_primary_10_1073_pnas_2119761119 crossref_primary_10_1097_INF_0000000000003413 crossref_primary_10_3390_v15040966 crossref_primary_10_1016_j_celrep_2021_109929 crossref_primary_10_3390_microbiolres14030093 crossref_primary_10_1093_cei_uxac009 crossref_primary_10_1016_j_ebiom_2022_104341 crossref_primary_10_3390_microorganisms9122578 crossref_primary_10_1016_j_cell_2021_01_007 crossref_primary_10_3389_fimmu_2022_856033 crossref_primary_10_3389_fimmu_2022_945021 crossref_primary_10_1016_j_trsl_2021_02_006 crossref_primary_10_1016_j_smim_2021_101507 crossref_primary_10_1016_j_isci_2021_103659 crossref_primary_10_3389_fimmu_2021_772239 crossref_primary_10_3390_v15010175 crossref_primary_10_1186_s12916_020_01887_1 crossref_primary_10_3389_fimmu_2023_1291664 crossref_primary_10_3390_vaccines11010123 crossref_primary_10_1177_17534259211043159 crossref_primary_10_3390_pathogens11020186 crossref_primary_10_1002_JLB_5COVA0620_370RR crossref_primary_10_1080_19490976_2022_2117503 crossref_primary_10_1016_j_ebiom_2021_103580 crossref_primary_10_3390_jcm11216272 crossref_primary_10_3389_fimmu_2024_1341600 crossref_primary_10_1371_journal_pone_0264124 crossref_primary_10_1080_21645515_2021_1953351 crossref_primary_10_1038_s41392_022_00996_y crossref_primary_10_1038_s43856_021_00039_7 crossref_primary_10_1038_s41591_021_01542_z crossref_primary_10_3389_fimmu_2021_656362 crossref_primary_10_1128_mbio_02722_23 crossref_primary_10_1128_mBio_03192_20 crossref_primary_10_1016_j_virol_2021_02_002 crossref_primary_10_1126_scitranslmed_abn3715 crossref_primary_10_1038_s41598_023_35471_3 crossref_primary_10_1093_cid_ciac934 crossref_primary_10_1016_j_celrep_2022_111496 crossref_primary_10_1038_s41598_021_95045_z crossref_primary_10_1016_j_virol_2022_08_010 crossref_primary_10_3390_cells10081843 crossref_primary_10_1126_science_abf4860 crossref_primary_10_3390_microorganisms9081643 crossref_primary_10_1111_pbi_13908 crossref_primary_10_1002_path_5642 crossref_primary_10_1080_22221751_2022_2146535 crossref_primary_10_3389_fimmu_2022_836449 crossref_primary_10_1016_j_chom_2021_12_005 crossref_primary_10_1177_0004563221992390 crossref_primary_10_2139_ssrn_3956430 crossref_primary_10_1016_j_biopha_2021_112282 crossref_primary_10_1093_ckj_sfab048 crossref_primary_10_1128_spectrum_02676_21 crossref_primary_10_1371_journal_pone_0261656 crossref_primary_10_4103_sjhs_sjhs_168_20 crossref_primary_10_1016_j_xcrm_2022_100685 crossref_primary_10_1126_sciimmunol_abl5842 crossref_primary_10_1111_sji_13345 crossref_primary_10_1038_s41467_022_31557_0 crossref_primary_10_3389_fimmu_2020_567710 crossref_primary_10_3390_ijms232214340 crossref_primary_10_1016_j_isci_2024_109210 crossref_primary_10_3389_fimmu_2020_610688 crossref_primary_10_3389_fimmu_2022_904686 crossref_primary_10_1080_21645515_2022_2047582 crossref_primary_10_1021_acsnano_4c02434 crossref_primary_10_3389_fimmu_2024_1355949 crossref_primary_10_1007_s11696_023_02795_3 crossref_primary_10_1080_19932820_2023_2209949 crossref_primary_10_3389_fimmu_2022_770982 crossref_primary_10_3889_oamjms_2022_9957 crossref_primary_10_1631_jzus_B2200049 crossref_primary_10_1126_scitranslmed_adf6598 crossref_primary_10_1038_s41541_023_00801_z crossref_primary_10_1126_sciimmunol_abf8891 crossref_primary_10_1126_science_abm0829 crossref_primary_10_1016_j_ijid_2023_11_008 crossref_primary_10_3389_fimmu_2022_889836 crossref_primary_10_1038_s41467_023_43152_y crossref_primary_10_3390_vaccines11020408 crossref_primary_10_7554_eLife_70330 crossref_primary_10_7189_jogh_11_03057 crossref_primary_10_1002_cti2_1306 crossref_primary_10_1016_j_tim_2021_03_016 crossref_primary_10_1016_j_isci_2024_110470 crossref_primary_10_1080_14787210_2021_1905519 crossref_primary_10_1016_j_cell_2021_02_010 crossref_primary_10_1093_labmed_lmab061 crossref_primary_10_3390_vaccines11040849 crossref_primary_10_1016_j_celrep_2022_110904 crossref_primary_10_1038_s41467_022_32298_w crossref_primary_10_3390_vaccines9020178 crossref_primary_10_1126_sciimmunol_abj2901 crossref_primary_10_3389_fimmu_2022_1038712 crossref_primary_10_3389_fimmu_2021_637651 crossref_primary_10_3389_fmed_2021_770381 crossref_primary_10_1016_j_ijid_2021_09_039 crossref_primary_10_4049_jimmunol_2100762 crossref_primary_10_1016_j_ebiom_2021_103495 crossref_primary_10_1007_s00253_023_12927_0 crossref_primary_10_3390_genes13091602 crossref_primary_10_3892_mmr_2024_13272 crossref_primary_10_1111_all_15441 crossref_primary_10_3390_v15010248 crossref_primary_10_1038_s41577_022_00809_x crossref_primary_10_14336_AD_2020_1104 crossref_primary_10_3201_eid2811_221041 crossref_primary_10_1111_trf_16327 crossref_primary_10_1126_sciadv_adk6425 crossref_primary_10_1093_infdis_jiac022 crossref_primary_10_1016_j_chom_2021_06_009 crossref_primary_10_1038_s41467_022_30649_1 crossref_primary_10_1021_acsnano_4c03075 crossref_primary_10_3389_fimmu_2021_660019 crossref_primary_10_3389_fimmu_2021_790415 crossref_primary_10_1080_21645515_2022_2055373 crossref_primary_10_3390_vaccines11030545 crossref_primary_10_1016_j_cell_2021_01_050 crossref_primary_10_3390_vaccines10060980 |
| Cites_doi | 10.1073/pnas.0403492101 10.1038/s41586-020-2456-9 10.1016/j.jmb.2020.04.009 10.1128/CDLI.2.5.590-597.1995 10.1016/j.cell.2020.05.015 10.4049/jimmunol.171.10.4969 10.1038/s41591-020-0913-5 10.1016/j.jim.2011.09.006 10.1016/j.immuni.2020.03.020 10.1038/ni.3533 10.1016/j.chom.2020.02.001 10.1016/j.immuni.2020.03.007 10.1101/2020.05.14.095414 10.1016/j.cell.2019.03.016 10.3390/pathogens8040167 10.1073/pnas.0800003105 10.1126/science.1085952 10.1155/2006/152612 10.1038/s41586-020-2598-9 10.1101/2020.05.20.106294 10.1371/journal.pone.0050366 10.1126/science.abc7424 10.1038/s41586-020-2196-x 10.1016/j.immuni.2019.06.024 10.1126/sciimmunol.abc8413 10.1128/JVI.00169-19 10.1038/s41591-020-0897-1 10.1080/22221751.2020.1762515 10.1038/s41586-020-2012-7 10.1038/s41591-020-0965-6 10.1086/422040 10.1016/j.chom.2020.03.002 10.1101/2020.05.24.20112300 10.1093/infdis/jiaa273 10.1016/S0140-6736(20)30183-5 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Nguyen-Contant et al. Copyright © 2020 Nguyen-Contant et al. 2020 Nguyen-Contant et al. |
| Copyright_xml | – notice: Copyright © 2020 Nguyen-Contant et al. – notice: Copyright © 2020 Nguyen-Contant et al. 2020 Nguyen-Contant et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1128/mBio.01991-20 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Memory B Cell Response to SARS-CoV-2 |
| EISSN | 2150-7511 |
| ExternalDocumentID | oai_doaj_org_article_0999ec747b4f4a81a0fdcfbb69764096 10.1128/mbio.01991-20 PMC7520599 32978311 10_1128_mBio_01991_20 |
| Genre | Journal Article Comparative Study Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: HHSN272201400005C – fundername: ; grantid: HHSN272201400005C |
| GroupedDBID | --- 0R~ 53G 5VS AAFWJ AAGFI AAUOK AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CITATION DIK E3Z EBS FRP GROUPED_DOAJ GX1 H13 HYE HZ~ KQ8 M48 O5R O5S O9- OK1 P2P PGMZT RHI RNS RPM RSF CGR CUY CVF ECM EIF M~E NPM RHF 7X8 5PM ADRAZ ADTOC C1A EJD UNPAY |
| ID | FETCH-LOGICAL-c453t-34db822ccf026e50d6f84a08eff1a3679e4522371dfcbb19f1b7f7bed8d5413a3 |
| IEDL.DBID | M48 |
| ISSN | 2161-2129 2150-7511 |
| IngestDate | Wed Aug 27 01:30:44 EDT 2025 Sun Sep 07 11:22:29 EDT 2025 Tue Sep 30 16:43:04 EDT 2025 Thu Jul 10 23:18:24 EDT 2025 Wed Feb 19 02:03:56 EST 2025 Tue Jul 01 01:52:45 EDT 2025 Thu Apr 24 23:06:35 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | COVID-19 IgG antibodies SARS-CoV-2 memory B cells spike protein |
| Language | English |
| License | Copyright © 2020 Nguyen-Contant et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c453t-34db822ccf026e50d6f84a08eff1a3679e4522371dfcbb19f1b7f7bed8d5413a3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-9435-8673 0000-0002-1599-5894 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1128/mBio.01991-20 |
| PMID | 32978311 |
| PQID | 2446672187 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0999ec747b4f4a81a0fdcfbb69764096 unpaywall_primary_10_1128_mbio_01991_20 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7520599 proquest_miscellaneous_2446672187 pubmed_primary_32978311 crossref_citationtrail_10_1128_mBio_01991_20 crossref_primary_10_1128_mBio_01991_20 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200925 |
| PublicationDateYYYYMMDD | 2020-09-25 |
| PublicationDate_xml | – month: 9 year: 2020 text: 20200925 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | mBio |
| PublicationTitleAlternate | mBio |
| PublicationYear | 2020 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 |
| References_xml | – ident: e_1_3_2_24_2 doi: 10.1073/pnas.0403492101 – ident: e_1_3_2_21_2 doi: 10.1038/s41586-020-2456-9 – ident: e_1_3_2_7_2 doi: 10.1016/j.jmb.2020.04.009 – ident: e_1_3_2_36_2 doi: 10.1128/CDLI.2.5.590-597.1995 – ident: e_1_3_2_10_2 doi: 10.1016/j.cell.2020.05.015 – ident: e_1_3_2_32_2 doi: 10.4049/jimmunol.171.10.4969 – ident: e_1_3_2_8_2 doi: 10.1038/s41591-020-0913-5 – ident: e_1_3_2_27_2 doi: 10.1016/j.jim.2011.09.006 – ident: e_1_3_2_28_2 doi: 10.1016/j.immuni.2020.03.020 – ident: e_1_3_2_34_2 doi: 10.1038/ni.3533 – ident: e_1_3_2_6_2 doi: 10.1016/j.chom.2020.02.001 – ident: e_1_3_2_3_2 doi: 10.1016/j.immuni.2020.03.007 – ident: e_1_3_2_11_2 doi: 10.1101/2020.05.14.095414 – ident: e_1_3_2_15_2 doi: 10.1016/j.cell.2019.03.016 – ident: e_1_3_2_33_2 doi: 10.3390/pathogens8040167 – ident: e_1_3_2_29_2 doi: 10.1073/pnas.0800003105 – ident: e_1_3_2_12_2 doi: 10.1126/science.1085952 – ident: e_1_3_2_25_2 doi: 10.1155/2006/152612 – ident: e_1_3_2_9_2 doi: 10.1038/s41586-020-2598-9 – ident: e_1_3_2_19_2 doi: 10.1101/2020.05.20.106294 – ident: e_1_3_2_26_2 doi: 10.1371/journal.pone.0050366 – ident: e_1_3_2_20_2 doi: 10.1126/science.abc7424 – ident: e_1_3_2_14_2 doi: 10.1038/s41586-020-2196-x – ident: e_1_3_2_35_2 doi: 10.1016/j.immuni.2019.06.024 – ident: e_1_3_2_31_2 doi: 10.1126/sciimmunol.abc8413 – ident: e_1_3_2_23_2 doi: 10.1128/JVI.00169-19 – ident: e_1_3_2_16_2 doi: 10.1038/s41591-020-0897-1 – ident: e_1_3_2_17_2 doi: 10.1080/22221751.2020.1762515 – ident: e_1_3_2_2_2 doi: 10.1038/s41586-020-2012-7 – ident: e_1_3_2_5_2 doi: 10.1038/s41591-020-0965-6 – ident: e_1_3_2_13_2 doi: 10.1086/422040 – ident: e_1_3_2_30_2 doi: 10.1016/j.chom.2020.03.002 – ident: e_1_3_2_18_2 doi: 10.1101/2020.05.24.20112300 – ident: e_1_3_2_22_2 doi: 10.1093/infdis/jiaa273 – ident: e_1_3_2_4_2 doi: 10.1016/S0140-6736(20)30183-5 |
| SSID | ssj0000331830 |
| Score | 2.6154287 |
| Snippet | The recent rapid worldwide spread of SARS-CoV-2 has established a pandemic of potentially serious disease in the highly susceptible human population. Key... The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19),... ABSTRACT The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019... |
| SourceID | doaj unpaywall pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Adult Antibodies, Viral - immunology B-Lymphocytes - immunology B-Lymphocytes - virology Betacoronavirus - immunology Convalescence Coronavirus Infections - immunology Coronavirus Nucleocapsid Proteins COVID-19 Cross Reactions Female Healthy Volunteers Host-Microbe Biology Humans IgG antibodies Immunoglobulin G - immunology Immunologic Memory Male memory B cells Middle Aged Nucleocapsid Proteins - immunology Pandemics Phosphoproteins Pneumonia, Viral - immunology Protein Interaction Domains and Motifs Protein Subunits SARS-CoV-2 Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - immunology spike protein |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJQQXxJsUioyE4EJoYjtx9thdUVqkItSlqLfIT1gpdSq6EdobP70zTnaVVUFcuEXJKLE9Y8839uQbQl6rSjKnhE_tRKhUiAlMKVXyVCO3FNfgIh3-KHzyuTw6E5_Oi_NRqS_MCevpgfuB20cE4wyAXi28UFWuMm-N17oEPwqxSSTbBjc2CqbiGszRVrM1qSar9i-mi_Z9FhN9sLb3yAlFrv4_AcybeZJ3unCpVr9U04yc0OF9cm9Aj_Sgb_UDcsuFh-R2X09y9Yj8ntMvyLuwCOmpU3Elo8ffP1IVLD3BlNoVndKZaxoUsz1vLI1VwmnczKfzg9N5Omu_pYweD1laAa5M01l3RSFkV5YObwb0TpctBfxI54zC-tPB4vCYnB1--Do7SocSC6kRBV-mXFgNEMEYD7GYKzJb-kqorHLe54qXcuKQcZ3L3HqjdT7xuZZeamcrW4D7U_wJ2QltcM8INTbzGrC6zLwTtuTaeMAGonCVZiBvEvJuPea1GfjHsQxGU8c4hFU1qqiOKqpZlpA3G_HLnnjjb4JTVOBGCPmy4w2wonqwovpfVpSQV2v11zC_8NBEBdd2VzXDA28IkyuZkKe9OWw-xRlunOV5QuSWoWy1ZftJWPyIHN6yYMiMk5C3G5O62U096ubu_-jmc3KX4X4BnqoVL8jO8mfn9gBULfXLOH-uAfpnIJk priority: 102 providerName: Directory of Open Access Journals – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdQJwQvML4DGzISghfcJY4TJ49dtbIhbZpWisZT5E-oyJKJJULliT-ds5NW7QaCtyi5JHZ8Pv8ud_4dQq9FxqkRzBKdM0EYy2FKiTQm0nFLxRKWSOM2Ch-fpIcz9uE8Oe-TaNxemPX4PZjOvQs5r4ehz8-h4JlvpS6ONEBbs5PT0WdXOA4ADeGJr7NLAb0QMMX5kkvz-v0ba4-n6P8TrryZHnmnrS7F4ocoy7W1Z3IfTZat7lJOvg3bRg7Vz2uEjv_s1ja616NPPOrU5QG6ZaqH6HZXj3LxCP2a4lPH2zCvyJkR3hLioy_vsag0PnYpuQu8j8emLJ2Y7nhnsa8yjn0wAE9HZ1Myrj8Rio_6LK8KjlTZanOFweUXGvdPBvSPmxoD_sRTisF-tWBcHqPZ5ODj-JD0JRqIYknckJhpCRBDKQu-nElCndqMiTAz1kYiTnluHGN7zCNtlZRRbiPJLZdGZzqB5VPET9CgqivzDGGlQysB6_PQGqbTWCoL2IIlJpMU5FWA3i0Hr1A9f7kro1EW3o-hWXEBn6vwH7WgYYDerMQvO-KOvwnuO01YCTm-bX8Cxqvop2_hcLRR4HpJZpnIIhFarayUKaA58JDTAL1a6lEB89MFXURl6vaqoC5gDm52xgP0tNOr1ati6n68RVGA-IbGbbRl80o1_-o5wHlCHbNOgN6udPNmN-VaN5__t-QLdJe6nwou9JbsoEHzvTW7gLwa-bKfd78B2uYpAQ priority: 102 providerName: Unpaywall |
| Title | S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32978311 https://www.proquest.com/docview/2446672187 https://pubmed.ncbi.nlm.nih.gov/PMC7520599 https://doi.org/10.1128/mbio.01991-20 https://doaj.org/article/0999ec747b4f4a81a0fdcfbb69764096 |
| UnpaywallVersion | publishedVersion |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVABX databaseName: American Society for Microbiology Open Access customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: AAUOK dateStart: 20100518 isFulltext: true titleUrlDefault: https://journals.asm.org/ providerName: American Society for Microbiology – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: GX1 dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2150-7511 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2150-7511 dateEnd: 20210131 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: M48 dateStart: 20200801 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2150-7511 dateEnd: 20250831 omitProxy: true ssIdentifier: ssj0000331830 issn: 2161-2129 databaseCode: M48 dateStart: 20100501 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6hVkAviDcuEC0Sggtu7fX6kQNCSUQfSKmqhqBwsvZZIhm7TWJBbvx0ZtZOaGi5cLEse-z1emd2vtnHN4S8FlnKjODW110ufM67YFIiiXyJ3FKRBBdpcKPw8CQ5GvNPk3jyh1Ko_YHzG0M7zCc1nhV7Py-XH8Dg3zcbYLL97_1ptRe4NTwMovdtcEoMFXzYIn3XKUeovMGKZfPvp3bInYjhKEgYbjgox-N_E_i8vobybl1eiOUPURRXHNTBfXKvRZa016jCA3LLlA_J7SbX5PIR-TWip8jJMC39MyNcL0ePzw-pKDUd4nLbJe3TgSkKFNMNpyx1GcSpG-ino97ZyB9UX3xGj9sVXCWcqaLWZk4hnBeatm8GZE8XFQVsSUeMQt9UQ8fxmIwPPn4eHPlt-gVf8Tha-BHXEuCDUhbiNBMHOrEZF0FmrA1FlKRdg2zsURpqq6QMuzaUqU2l0ZmOwTWK6AnZKqvSPCNU6cBKwPFpYA3XSSSVBdzAY5NJBvLKI-9W_zxXLTc5psgochejsCzH1spda-Us8MibtfhFQ8rxL8E-NuBaCLm03YVqdp63ppkjRjYKwirJLRdZKAKrlZUyAaQG0W_ikVer5s_B9nBCRZSmquc5w8lwCKGz1CNPG3VYF7VSJ4-kG4qy8S2bd8rpN8fvncYMWXM88natUterKa9Uc_e_y3hOdhgOIOA0W_yCbC1mtXkJKGshO250Ao6Hk7DjbKlDtscnp72vvwFQXStt |
| linkProvider | Scholars Portal |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdQJwQvML4DGzISghfcJY4TJ49dtbIhbZpWisZT5E-oyJKJJULliT-ds5NW7QaCtyi5JHZ8Pv8ud_4dQq9FxqkRzBKdM0EYy2FKiTQm0nFLxRKWSOM2Ch-fpIcz9uE8Oe-TaNxemPX4PZjOvQs5r4ehz8-h4JlvpS6ONEBbs5PT0WdXOA4ADeGJr7NLAb0QMMX5kkvz-v0ba4-n6P8TrryZHnmnrS7F4ocoy7W1Z3IfTZat7lJOvg3bRg7Vz2uEjv_s1ja616NPPOrU5QG6ZaqH6HZXj3LxCP2a4lPH2zCvyJkR3hLioy_vsag0PnYpuQu8j8emLJ2Y7nhnsa8yjn0wAE9HZ1Myrj8Rio_6LK8KjlTZanOFweUXGvdPBvSPmxoD_sRTisF-tWBcHqPZ5ODj-JD0JRqIYknckJhpCRBDKQu-nElCndqMiTAz1kYiTnluHGN7zCNtlZRRbiPJLZdGZzqB5VPET9CgqivzDGGlQysB6_PQGqbTWCoL2IIlJpMU5FWA3i0Hr1A9f7kro1EW3o-hWXEBn6vwH7WgYYDerMQvO-KOvwnuO01YCTm-bX8Cxqvop2_hcLRR4HpJZpnIIhFarayUKaA58JDTAL1a6lEB89MFXURl6vaqoC5gDm52xgP0tNOr1ati6n68RVGA-IbGbbRl80o1_-o5wHlCHbNOgN6udPNmN-VaN5__t-QLdJe6nwou9JbsoEHzvTW7gLwa-bKfd78B2uYpAQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=S+Protein-Reactive+IgG+and+Memory+B+Cell+Production+after+Human+SARS-CoV-2+Infection+Includes+Broad+Reactivity+to+the+S2+Subunit&rft.jtitle=mBio&rft.au=Nguyen-Contant%2C+Phuong&rft.au=Embong%2C+A.+Karim&rft.au=Kanagaiah%2C+Preshetha&rft.au=Chaves%2C+Francisco+A.&rft.date=2020-09-25&rft.pub=American+Society+for+Microbiology&rft.eissn=2150-7511&rft.volume=11&rft.issue=5&rft_id=info:doi/10.1128%2FmBio.01991-20&rft_id=info%3Apmid%2F32978311&rft.externalDocID=PMC7520599 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2161-2129&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2161-2129&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2161-2129&client=summon |